- In its results for the six months ended 30 September 2019, Mediclinic International announced a 9% growth in revenue.

The company also declared an interim dividend maintained at 3.20p per share.

Adjusted EBITDA was up 4% at £222m, while adjusted earnings per share were flat at 10.3p.

According to the half year report, adjusted operating profit remained flat at £137m, reflecting increased depreciation charges associated with infrastructure and technology investments.

Reported operating profit rose 264% to £142m, reflecting prior year period non-cash Hirslanden impairment charges of £98m

Story provided by